EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Evommune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.4%
35M of 36M shares
Institutional holders
105
41 new, 17 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
7 buys · 9 sales
Net bought $67.88M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 5,288,313 | 14.70% | 13D (active) amendment | Feb 12, 2026 |
| Rajeev Shah | 3,494,638 | 9.70% | 13D (active) amendment | Feb 12, 2026 |
| Peter Kolchinsky | 3,458,770 | 11.00% | 13D (active) | Nov 7, 2025 |
| Nan Fung Group Holdings Limited | 3,435,599 | 10.90% | 13G (passive) | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 1,940,939 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Point72 Asset Management, L.P. | 1,910,489 | 5.30% | 13G (passive) | Jul 15, 2026 |
| BioDiscovery 6 FPCI | 1,897,362 | 6.00% | 13G (passive) | Nov 7, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EVMN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,288,313 | 14.57% | $70.28M | +358,680 | 8.15% |
| Ra Capital Management, L.P. | 3,494,638 | 9.63% | $46.44M | – | 0.40% |
| Price T Rowe Associates Inc /Md/ | 1,940,939 | 5.35% | $25.80K | +821,918 | 0.00% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,926,943 | 5.31% | $25.61M | – | 8.32% |
| JPMorgan Chase & Co | 1,553,132 | 4.28% | $23.37M | +93,712 | 0.00% |
| Rtw Investments, LP | 1,502,235 | 4.14% | $19.96M | – | 0.17% |
| Nan Fung Group Holdings Ltd | 1,441,032 | 3.97% | $19.15M | – | 14.56% |
| Point72 Asset Management, L.P. | 1,435,049 | 3.95% | $19.07M | +1,398,472 | 0.02% |
| Andera Partners | 1,391,990 | 3.84% | $18.50M | −505,372 | 8.96% |
| Eventide Asset Management, LLC | 1,209,129 | 3.33% | $16.07M | – | 0.21% |
| Vestal Point Capital, LP | 1,000,000 | 2.76% | $13.29M | New | 0.31% |
| Jupiter Topco LLC | 896,700 | 2.47% | $11.92M | New | 0.00% |
| BlackRock, Inc. | 886,538 | 2.44% | $11.78M | +212,967 | 0.00% |
| Vanguard Capital Management LLC | 881,895 | 2.43% | $11.72M | +426,844 | 0.00% |
| Baker Bros. Advisors LP | 847,390 | 2.33% | $11.26M | – | 0.06% |
| Defilade Capital Management, L.P. | 793,145 | 2.19% | $10.54M | +114,556 | 1.41% |
| American Century Companies Inc | 755,018 | 2.08% | $10.03M | +262,080 | 0.00% |
| Alyeska Investment Group, L.P. | 704,425 | 1.94% | $9.36M | −21,937 | 0.02% |
| Balyasny Asset Management L.P. | 457,015 | 1.26% | $6.07M | New | 0.01% |
| Velan Capital Investment Management LP | 451,255 | 1.24% | $6.00M | +5,000 | 3.65% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 105 | 35M | 95.4% | 41 / 36 | 13 / 17 | 9M | 7M |
| Q1 2026 | 84 | 35M | 95.8% | 37 / 26 | 11 / 10 | 10M | 2M |
| Q4 2025 | 59 | 27M | 74.9% | 59 / 0 | 0 / 0 | 27M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EVMN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund | 940,119 | 2.59% | $12.49M | 0.70% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 739,068 | 2.04% | $9.82M | 0.00% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 711,122 | 1.96% | $9.45M | 0.06% | Jun 30, 2026 |
| Small Cap Growth Fund | 567,828 | 1.56% | $6.39M | 0.11% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 554,355 | 1.53% | $7.37M | 0.28% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 346,633 | 0.96% | $4.61M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 332,110 | 0.92% | $4.41M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 325,000 | 0.90% | $3.66M | 0.13% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 258,200 | 0.71% | $3.43M | 0.03% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 176,234 | 0.49% | $2.34M | 0.14% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 138,618 | 0.38% | $1.56M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 126,549 | 0.35% | $1.68M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 119,063 | 0.33% | $1.58M | 0.01% | Jun 30, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 92,684 | 0.26% | $2.15M | 0.17% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 58,033 | 0.16% | $1.35M | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Luis C. Pena | President & CEO, Director | 630,458 | 1.74% | Jun 24, 2026 |
| Eugene Bauer | Chief Medical Officer, Director | 270,818 | 0.75% | Apr 17, 2026 |
| Kyle Carver | Chief Financial Officer | 60,335 | 0.17% | Jul 10, 2026 |
| Janice Suzann Drew | Chief of Dev. Operations | 71,633 | 0.20% | Jun 24, 2026 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | 46,403 | 0.13% | Jun 24, 2026 |
| Gregory S. Moss | Chief Business & Legal Officer | 64,010 | 0.18% | Jun 1, 2026 |
| Arthur S. Kirsch | Director | 10,000 | 0.03% | Jul 8, 2026 |
| Benjamin F. McGraw Iii | Director | – | – | Jun 3, 2026 |
| David E. Cohen | Director | 17,609 | 0.05% | Jun 3, 2026 |
| 7 Cooperative UA LSP | Director, 10% owner | 10,217,946 | 28.15% | Feb 19, 2026 |
| Weegen Felice Isabel Verduyn-van | Director, 10% owner | 5,288,313 | 14.57% | Feb 18, 2026 |
| Peter Kolchinsky | Director | – | – | Feb 17, 2026 |
| Capital Healthcare Fund LP RA | Director | 2,710,293 | 7.47% | Feb 17, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | – | – | Feb 17, 2026 |
| Rajeev M. Shah | Director | – | – | Feb 17, 2026 |
| Ra Capital Management, L.P. | Director | 784,345 | 2.16% | Feb 17, 2026 |
| Robert Lorne Hopfner | Director, 10% owner | 3,372,001 | 9.29% | Dec 22, 2025 |
| Pivotal bioVenture Partners Fund I, L.P. | Director, 10% owner | – | – | Nov 12, 2025 |
| bioVenture Partners Fund I. U.G.P. Ltd Pivotal | Director, 10% owner | – | – | Nov 12, 2025 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Director, 10% owner | 294,502 | 0.81% | Nov 12, 2025 |
| Derek DiRocco | Director | – | – | Nov 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kyle Carver Chief Financial Officer | Jul 8, 2026 | Buy | +1,000 | $13.26 | $13.26K | 60,335 |
| Arthur S. Kirsch Director | Jul 7, 2026 | Buy | +10,000 | $13.30 | $133.00K | 10,000 |
| Luis C. Pena President & CEO, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −7,438 | $22.71 | $168.92K | 630,458 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,488 | $22.50 | $33.48K | 46,403 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 22, 2026 | Option exercise | +1,488 | $3.84 | $5.71K | 47,891 |
| Janice Suzann Drew Chief of Dev. Operations | Jun 22, 2026 | Option exercise | +3,839 | $3.84 | $14.74K | 71,633 |
| Janice Suzann Drew Chief of Dev. Operations | Jun 22, 2026 | Sale(10b5-1 plan) | −20,000 | $22.63 | $452.60K | 67,794 |
| Janice Suzann Drew Chief of Dev. Operations | Jun 22, 2026 | Option exercise | +16,161 | $2.99 | $48.32K | 87,794 |
| David E. Cohen Director | Jun 2, 2026 | Sale(10b5-1 plan) | −600 | $21.38 | $12.83K | 17,609 |
| David E. Cohen Director | Jun 2, 2026 | Sale(10b5-1 plan) | −5,456 | $20.21 | $110.27K | 18,209 |
| Luis C. Pena President & CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −16,787 | $22.74 | $381.74K | 637,896 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −16,687 | $22.74 | $379.46K | 46,403 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Jun 1, 2026 | Option exercise | +13,512 | $3.84 | $51.89K | 63,090 |
| Kyle Carver Chief Financial Officer | May 28, 2026 | Sale(10b5-1 plan) | −18,175 | $22.84 | $415.12K | 59,335 |
| Kyle Carver Chief Financial Officer | May 28, 2026 | Option exercise | +15,000 | $2.99 | $44.85K | 77,510 |
| Gregory S. Moss Chief Business & Legal Officer | May 28, 2026 | Sale(10b5-1 plan) | −14,223 | $22.83 | $324.71K | 60,835 |
| Gregory S. Moss Chief Business & Legal Officer | May 28, 2026 | Option exercise | +14,223 | $1.71 | $24.32K | 75,058 |
| 7 Cooperative UA LSP Director, 10% owner | Feb 17, 2026 | Award | +358,680 | $27.88 | $10.00M | 5,288,313 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner | Feb 17, 2026 | Award | +358,680 | $27.88 | $10.00M | 5,288,313 |
| Capital Healthcare Fund LP RA Director | Feb 17, 2026 | Award | +35,868 | $27.88 | $1,000.00K | 2,710,293 |
| Robert Lorne Hopfner Director, 10% owner | Dec 19, 2025 | Buy | +1,000 | $17.35 | $17.35K | 4,026 |
| Janice Suzann Drew EVP, Operations | Dec 9, 2025 | Tax withholding | −5,074 | $17.84 | $90.52K | 67,794 |
| Gregory S. Moss Chief Business & Legal Officer | Dec 9, 2025 | Tax withholding | −13,624 | $17.84 | $243.05K | 60,835 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Dec 9, 2025 | Tax withholding | −7,513 | $17.84 | $134.03K | 49,578 |
| Eugene Bauer Chief Medical Officer, Director | Dec 9, 2025 | Tax withholding | −1,478 | $17.84 | $26.37K | 270,818 |
| Luis C. Pena President & CEO, Director | Dec 9, 2025 | Tax withholding | −28,138 | $17.84 | $501.98K | 654,683 |
| Kyle Carver Chief Financial Officer | Dec 9, 2025 | Tax withholding | −13,290 | $17.84 | $237.09K | 62,510 |
| Luis C. Pena President & CEO, Director | Nov 7, 2025 | Conversion | +24,225 | – | – | 682,821 |
| 7 Cooperative UA LSP 10% owner | Nov 7, 2025 | Buy | +1,562,500 | $16.00 | $25.00M | 4,929,633 |
| 7 Cooperative UA LSP 10% owner | Nov 7, 2025 | Conversion | +3,367,133 | – | – | 3,367,133 |
| Eugene Bauer Chief Medical Officer, Director | Nov 7, 2025 | Conversion | +25,812 | – | – | 272,296 |
| Kyle Carver Chief Financial Officer | Nov 7, 2025 | Conversion | +3,175 | – | – | 75,800 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Buy | +92,904 | $16.00 | $1.49M | 784,345 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Buy | +1,157,096 | $16.00 | $18.51M | 2,674,425 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +691,441 | – | – | 691,441 |
| Ra Capital Management, L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +1,517,329 | – | – | 1,517,329 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +1,632,441 | – | – | 1,632,441 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +294,502 | – | – | 294,502 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +1,441,032 | – | – | 1,441,032 |
| Robert Lorne Hopfner Director, 10% owner | Nov 7, 2025 | Conversion | +3,026 | – | – | 3,026 |
| David E. Cohen Director | Nov 7, 2025 | Conversion | +6,056 | – | – | 23,665 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner | Nov 7, 2025 | Buy | +1,562,500 | $16.00 | $25.00M | 4,929,633 |
| Weegen Felice Isabel Verduyn-van Director, 10% owner | Nov 7, 2025 | Conversion | +3,367,133 | – | – | 3,367,133 |
| Jeegar Pravinkumar Patel Chief Scientific Officer | Nov 7, 2025 | Conversion | +3,175 | – | – | 57,091 |
| Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +294,502 | – | – | 294,502 |
| Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +1,441,032 | – | – | 1,441,032 |
| Pivotal bioVenture Partners Fund I G.P., L.P. Director, 10% owner | Nov 7, 2025 | Conversion | +1,632,441 | – | – | 1,632,441 |
| Janice Suzann Drew EVP, Operations | Nov 7, 2025 | Conversion | +1,587 | – | – | 72,868 |
| Gregory S. Moss Chief Business & Legal Officer | Nov 7, 2025 | Conversion | +3,175 | – | – | 3,175 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Drew Janice Officer | Jun 22, 2026 | 20,000 | $427.20K | Jun 22, 2026 | Exercise of Stock Options |
| Cohen David Director | Jun 2, 2026 | 9,258 | $205.25K | Jun 2, 2026 | Pre-IPO Purchase of Common Shares |
| Patel Jeegar Officer | Jun 1, 2026 | 18,175 | $422.21K | Jun 1, 2026 | Exercise of Stock Options |
| Pena Luis Director, Officer | Jun 1, 2026 | 24,225 | $562.75K | Jun 1, 2026 | Pre-IPO Purchase of Common Shares |
| Carver Kyle Officer | May 28, 2026 | 25,675 | $599.25K | May 28, 2026 | Exercise of Stock Options |
| Moss Gregory Officer | May 28, 2026 | 14,223 | $331.96K | May 28, 2026 | Exercise of Stock Options |